CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Kentucky mom shares her colon cancer journey to save others
March 26, 2025
University of Cincinnati Cancer Center patient Patty Goering and physician researcher Tahir Latif spoke with WLWT about Goering's story of being diagnosed and treated for colon cancer at a young age.
UC Blue Ash professor combines service and adventure in trip to...
March 26, 2025
Olivia Enriquez began 2025 with a surprise request that included a trip halfway around the world to help a community in need.
CCM Composition Professor awarded 2025 Wachtmeister Award
March 25, 2025
The UC College-Conservatory of Music congratulates Douglas Knehans, Professor of Composition, who was recently named the recipient of the 2025 Wachtmeister Award. Awarded every two years by the Virginia Center for the Creative Arts (VCCA), the prize includes a 30 day residency at Mt. San Angelo in the foothills of Virginia’s Blue Ridge Mountains, as well as a $1,000 honorarium and a travel stipend.